Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
ELIQUIS (apixaban)
(https://eliquis.com) 📸 Data Snapshot: May 29, 2026Analyze the raw signals below. How would a machine score this business’s credibility?
Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.
🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE Rx ELIQUIS® (apixaban) Home Page | Safety Info (https://eliquis.com)
Rx ELIQUIS® (apixaban) Home Page | Safety Info
Learn more about Rx ELIQUIS® and the conditions it is used to help treat. Review important safety information, benefits and risks, including BOXED WARNINGS.
HEADER_HEADING_REPEATED_FOOTER (https://eliquis.com/vte/)
HEADER_HEADING_REPEATED_FOOTER (https://eliquis.com/pediatric/)
HEADER_HEADING_REPEATED_BODY_FOOTER (https://eliquis.com/afib/)
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://eliquis.com) Rx ELIQUIS® (apixaban) Home Page | Safety Info
[IMG: indication-nvaf] Nonvalvular AFib Reduce the risk of stroke due to AFib, a type of irregular heartbeat, not caused by a heart valve problem GET STARTED [IMG: indication-dvt-pe] DVT/PE Treat blood clots in the veins of the legs/lungs and reduce the risk of them occurring again GET STARTED [IMG: Indication-hip-knee] Hip/Knee Replacement Decrease risk of DVT blood clots after hip or knee replacement surgery GET STARTED > ELIQUIS may cause serious side effects, including increased risk of blood clots if you stop taking ELIQUIS. ELIQUIS lowers your chance of having a stroke by helping to prevent clots from forming. Do not stop taking ELIQUIS without talking to the healthcare provider who prescribed it for you. Stopping ELIQUIS increases your risk of having a stroke. ELIQUIS may need to be stopped prior to surgery or a medical or dental procedure. Your healthcare provider will tell you when you should stop taking ELIQUIS and when you may start taking it again. If you have to stop taking ELIQUIS, your healthcare provider may prescribe another medicine to help prevent a blood clot from forming. Important facts about ELIQUIS® (apixaban) tablets and ELIQUIS® SPRINKLE (apixaban) ELIQUIS may cause serious side effects, including increased risk of blood clots if you stop taking ELIQUIS. ELIQUIS lowers your chance of having a stroke by helping to prevent clots from forming. Do not stop taking ELIQUIS without talking to the healthcare provider who prescribed it for you. Stopping ELIQUIS increases your risk of having a stroke. ELIQUIS may need to be stopped prior to surgery or a medical or dental procedure. Your healthcare provider will tell you when you should stop taking ELIQUIS and when you may start taking it again. If you have to stop taking ELIQUIS, your healthcare provider may prescribe another medicine to help prevent a blood clot from forming. This is a summary of important safety information that you need to know about ELIQUIS. Keep this document in a safe place, so you can refer to it before and during your treatment. Look out for the following icons as you read: Talk to your healthcare team Call a healthcare provider right away Helpful information to remember What is the most important information I should know about ELIQUIS? ELIQUIS may cause serious side effects, including: Increased risk of blood clots if you stop taking ELIQUIS ELIQUIS lowers your chance of having a stroke by helping to prevent clots from forming. If you stop taking ELIQUIS, you may have an increased risk of a clot forming in your blood. Do not stop taking ELIQUIS without talking to the healthcare provider who prescribed it to you. Stopping ELIQUIS increases your risk of having a stroke. Talk to your healthcare team before any medical procedures. ELIQUIS may need to be stopped before surgery or a medical or dental procedure. Your healthcare provider will tell you when you should stop taking ELIQUIS and when you may start taking it again. If you have to stop taking ELIQUIS, your healthcare provider may prescribe another medicine to help prevent a blood clot from forming. Bleeding ELIQUIS can cause bleeding, which can be serious, and may lead to death. This is because ELIQUIS is a blood thinner medicine that reduces blood clotting. While taking ELIQUIS, you may bruise more easily and it may take longer than usual for any bleeding to stop. You may have a higher risk of bleeding if you take ELIQUIS and take other medicines that increase your risk of bleeding, such as: Aspirin or aspirin-containing products Long-term (chronic) nonsteroidal anti-inflammatory drugs (called NSAIDs) Warfarin sodium Any medicine that contains heparin Clopidogrel Selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) Other medicines to help prevent or treat blood clots Tell your healthcare provider if you take any of these medicines. Call your healthcare provider or get medical help right away if you or your child have any of these signs or symptoms of bleeding when taking ELIQUIS: Unexpected bleeding or bruising or bleeding that lasts a long time, such as: Unusual bleeding from the gums Nosebleeds that happen often Menstrual or vaginal bleeding that is heavier than normal Bleeding that is severe or you cannot control Red, pink, or brown urine Red or black stools (looks like tar) Coughing up or vomiting blood or blood clots Vomit that looks like coffee grounds Unexpected pain, swelling, or joint pain Headaches Feeling dizzy or weak Spinal or epidural blood clots (hematoma) People who take a blood thinner medicine like ELIQUIS, and have medicine injected into their spinal or epidural area, or have a spinal puncture, have a risk of forming a blood clot that can cause long-term or permanent loss of the ability to move (paralysis). Your risk of developing a spinal or epidural blood clot is higher if: A thin tube called an epidural catheter is placed in your back to give you certain medicine You take NSAIDs or a medicine to prevent blood from clotting You have a history of difficult or repeated epidural or spinal punctures You have a history of problems with your spine or have had surgery on your spine If you take ELIQUIS and receive spinal anesthesia or have a spinal puncture, your healthcare provider should watch you closely for symptoms of spinal or epidural blood clots or bleeding. Tell your healthcare provider right away if you have any of these signs or symptoms when taking ELIQUIS: Back pain Tingling, numbness, or muscle weakness, especially in your legs and feet Loss of control of the bowels or bladder (incontinence) Talk to your healthcare provider about any side effect that may be bothering you or that does not go away. These are not all of the possible side effects of ELIQUIS. Call your healthcare provider for medical advice about side effects. You are encouraged to report any side effects to the FDA at 1-800-FDA-1088. Who should not take ELIQUIS? ELIQUIS is not for patients who: have artificial heart valves have antiphospholipid syndrome (APS), especially with positive triple antibody testing currently have certain types of abnormal bleeding have had a severe allergic reaction to ELIQUIS or any of the ingredients What should I discuss with my healthcare team before starting ELIQUIS? Talk to your healthcare team if you or your child: Have or ever had bleeding problems Have kidney or liver problems Have antiphospholipid syndrome (APS) Are pregnant or plan to become pregnant. It is not known if ELIQUIS will harm your unborn baby Tell your healthcare provider right away if you become pregnant during treatment with ELIQUIS. Taking ELIQUIS during pregnancy may increase the risk of bleeding in you or your unborn baby. Females who are able to become pregnant: talk with your healthcare provider about pregnancy planning, and your risk of severe uterine bleeding if you are treated with ELIQUIS. Tell your healthcare provider if you are breastfeeding or plan to breastfeed. It is not known if ELIQUIS passes into your breast milk. Do not breastfeed during treatment with ELIQUIS. Talk to your healthcare provider about the best way to feed your baby during treatment with ELIQUIS. Tell your healthcare team about all the medicines you or your child take, including any: prescription medicines over-the-counter medicines vitamins herbal supplements During treatment, make sure you talk to your healthcare team before you begin to take any new medication. What are the possible serious side effects of ELIQUIS? The most common side effect of ELIQUIS in adults was bleeding. The most common side effects of ELIQUIS in children include: headache, vomiting, heavy menstrual bleeding. How should I take ELIQUIS? Take ELIQUIS exactly as prescribed by your healthcare provider. Twice daily Do not change your dose or stop taking ELIQUIS unless your healthcare provider tells you to. What if I miss a dose of ELIQUIS? If you or your child misses a dose of ELIQUIS, take it as soon as you remember on the same day. Do not take two doses of ELIQUIS at the same time to make up for a missed dose. Return to your usual dosing schedule the next day. For children who take ELIQUIS: See the detailed Instructions for Use that comes with ELIQUIS SPRINKLE for oral suspension or ELIQUIS tablets for oral suspension for information on how to prepare and give a dose of ELIQUIS to children who weigh less than 77 pounds (35 kg). Always give ELIQUIS exactly as your child’s healthcare provider or pharmacist has told you. The dose of ELIQUIS is based on your child’s body weight. Your child’s healthcare provider may need to change your child’s dose as their weight changes. Do not change your child’s dose without talking with the healthcare provider. If your child vomits or spits up within 30 minutes after taking ELIQUIS, repeat the dose. If your child vomits or spits up more than 30 minutes after taking ELIQUIS, do not repeat the dose. Continue to give the next ELIQUIS dose at the next scheduled time. Contact the healthcare provider if your child repeatedly vomits or spits up after taking ELIQUIS. When should I refill my prescription? Do not stop taking ELIQUIS without first talking with your healthcare provider. Do not run out of ELIQUIS. Refill your prescription before you run out. When leaving the hospital following hip or knee replacement, be sure that you will have ELIQUIS available to avoid missing any doses. ELIQUIS is available in two different tablets. Your healthcare provider will determine what dose is right for you. 2.5 mg tablet Yellow, round OR 5 mg tablet Pink, oval On one side of each film-coated tablet, there is a number indicating the dosage strength of the tablet (in milligrams). On the other side, there is a medication identification number. ELIQUIS is also available as ELIQUIS SPRINKLE, a capsule containing a powder for oral suspension, or as a film-coated tablet for oral suspension for pediatric patients. 0.15 mg capsule Yellow, opaque OR 0.5 mg tablet Pink, round Note: Images do not represent actual tablet or capsule size. The capsule is printed with a medication identification number. What is ELIQUIS? ELIQUIS is a prescription medicine used in adults to: Reduce the risk of stroke and blood clots in people who have atrial fibrillation (AFib), a type of irregular heartbeat, not caused by a heart valve problem. Treat blood clots in the veins of the legs (deep vein thrombosis – DVT) or lungs (pulmonary embolism – PE), and reduce the risk of them occurring again after receiving treatment for blood clots. Help prevent a blood clot in the legs (DVT) and lungs (PE) of people who have just had hip or knee replacement surgery. ELIQUIS is a prescription medicine used in children from birth and older to: Treat blood clots in the veins of the legs and lungs (venous thromboembolism) after at least 5 days of initial coagulant treatment, and reduce the risk of them occurring again. ELIQUIS was not studied and is not recommended in children who weigh less than 5.7 pounds (2.6 kg). Please see U.S. Full Prescribing Information, including Boxed WARNINGS and Medication Guide. The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries. The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
SUB-PAGE · THIN (https://eliquis.com/vte/)
[H1] Page Not Found We are sorry. The page you requested on hcp.eliquis.com did not load properly or is currently unavailable.GO TO HOME
SUB-PAGE · THIN (https://eliquis.com/pediatric/)
[H1] Page Not Found We are sorry. The page you requested on hcp.eliquis.com did not load properly or is currently unavailable.GO TO HOME
SUB-PAGE · THIN (https://eliquis.com/afib/)
[H1] Page Not Found We are sorry. The page you requested on hcp.eliquis.com did not load properly or is currently unavailable.GO TO HOME
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 7 | 0 |
| /vte/ | 6 | 0 |
| /pediatric/ | 6 | 0 |
| /afib/ | 6 | 0 |
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Your Diagnosis
Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.
Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)
These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: ELIQUIS (apixaban) (eliquis.com)
Eliquis presents a regulatory fortress built on a technical swamp. While the safety data is dense and high-substance, the 75% failure rate of its internal clinical navigation makes the site’s claims of being a primary resource for patients feel like hollow marketing.
Immediately resolve the 404 errors on the /vte/, /pediatric/, and /afib/ sub-pages to restore the promised signal. Implement Organization and Drug schema to provide a machine-readable authority footprint. Replace the generic review count widget with links to actual peer-reviewed clinical trial results. Add a specific source citation (e.g., IMS health data) with a date for the ‘#1 Prescribed’ claim to move it from fluff to substance.
The site strongly matches the Pharma & Biotech category, characterized by extensive mandatory safety disclosures and clinical indications. The presence of Boxed WARNINGS and specific dosage strengths (2.5 mg and 5 mg) confirms its role as a regulated prescription medicine platform.
“The score is driven primarily by the total collapse of Semantic Coherence and Identity & Authority. While Information Density is high for safety content, the technical failure of the sub-pages (404 errors) and the presence of unverified review counts (Trust Theatre) create a high BS-profile despite the brand's legitimate pharmaceutical status.”
This training module utilizes a snapshot of public data from ELIQUIS (apixaban), captured on May 29, 2026, to demonstrate how machine logic evaluates different types of business narratives.
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.
Notice to ELIQUIS (apixaban): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.
Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://eliquis.com to view the most current version of its content and learn from the source what this company is about and what it offers.